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Six antigen detection-based rapid influenza point-of-
care tests were compared for their ability to detect 
avian influenza A(H7N9) virus. The sensitivity of at 
least four tests, standardised by viral infectivity 
(TCID50) or RNA copy number, was lower for the influ-
enza A(H7N9) virus than for seasonal A(H3N2), A(H1N1)
pdm09 or other recent avian A(H7) viruses. Comparing 
detection limits of A(H7N9) virus with Ct values of 
A(H7N9) clinical specimens suggests the tests would 
not have detected most clinical specimens.
Human infections with influenza viruses derived directly 
from wild birds or poultry are relatively rare, although 
since 2003, over 600 human infections with influenza 
A(H5N1) viruses have been detected, many of which 
were fatal [1]. During the same period, a small num-
ber of influenza A(H7) virus infections worldwide have 
also occurred in humans upon contact with infected 
poultry, generally resulting in mild symptoms such as 
conjunctivitis with occasional respiratory involvement 
and one death [2-4]. In contrast, China announced in 
March 2013 human infections with a novel reassortant 
avian influenza A(H7N9) virus which caused severe 
pneumonia resulting in a number of deaths [5]. Cases 
have occurred predominantly in men over 60 years of 
age living in urban areas, and most cases had a history 
of recent contact with poultry or poultry products [5]. 
By 16 May 2013, 131 human cases of influenza A(H7N9) 
virus infection, in 10 provinces and municipalities in 
eastern China, had been reported to the World Health 
Organization (WHO), of which 32 had resulted in death 
[6]. To date there have not been any reports of sus-
tained human-to-human transmission of the influenza 
A(H7N9) virus, but the rapid emergence of the virus has 
led to significant concerns that it could in the future 
acquire human transmissibility and spread globally, 
causing the next influenza pandemic.
Rapid testing and diagnosis of possible human influ-
enza A(H7N9) virus infections is an important diagnos-
tic and public health task. An accurate diagnosis will 
allow the timely administration of antiviral therapy 
[7,8] and may also enable the quarantining of infected 
cases to prevent further spread of the virus. Real-time 
PCR is now considered the gold standard laboratory-
based assay for the detection of influenza virus infec-
tions due to its high sensitivity and specificity [6] and, 
although such assays have already been developed 
for the detection of influenza A(H7N9) virus [6], they 
require a high level of laboratory expertise and may 
not be available in all places where cases occur. 
Point-of-care tests (POCTs) based on antigen detection, 
however, are simple to use and are designed for use 
in a medical clinic or outpatient setting, enabling the 
rapid testing of patient specimens within 15 minutes 
[9]. POCTs have mostly been licensed for detection of 
seasonal human influenza viruses, for which they gen-
erally have good specificity but low sensitivity [10]. 
Recently however, some POCTs have been specifically 
developed to utilise automated readers which have 
resulted in improved sensitivity. For public health pur-
poses, it is important to determine whether the new or 
existing POCTs can detect the novel influenza A(H7N9) 
virus, particularly as previous studies have found that 
some POCTs had poorer sensitivity in detecting avian 
influenza strains compared to circulating human sea-
sonal influenza strains [9]. If POCTs could reliably 
detect influenza A(H7N9) virus at clinically relevant 
levels, they would be a useful adjunct to real-time PCR 
in the detection of possible human cases, especially 
where technical resources are limited.
We evaluated six widely available POCTs that are 
based on detection of the nucleoprotein antigen 
(Table 1) for their ability to detect the avian influ-
enza A(H7N9) virus A/Anhui/01/2013 [5], compared 
with three other low pathogenic avian influenza A(H7) 
viruses (A/Northern Shoveller/Egypt-EMC/1/2012, A/
Mallard/Netherlands/4/2010 and A/Mallard/Lithuania-
EMC/2/2010), two human seasonal influenza A(H3N2) 
(A/Sydney/506/2013 and A/Victoria/361/2011) and two 
influenza A(H1N1)pdm09 viruses (A/Auckland/1/2009 
and A/Brisbane/292/2010). 
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Methods
All viruses were cultured in Madin-Darby Canine Kidney 
(MDCK) cells at a low multiplicity of infection for at 
least one passage before testing. All viruses were har-
vested at near full cytopathic effect (CPE), supernatant 
was centrifuged at low speed to remove cell debris, 
and viruses were frozen at -70°C prior to testing. A 
mean tissue culture infectious dose 50 (TCID50) per mL 
was determined for each virus, based on at least three 
independent assays. Viruses were standardised to an 
infectivity titre of 1x106 TCID50/mL and then diluted in 
phosphate-buffered saline (PBS) in half-log10 dilutions. 
Real-time RT-PCR analysis was conducted on each 
virus dilution to determine a cycle threshold (Ct) value 
and RNA copy number, using an Applied Biosystems 
7500 Fast cycler and the real-time RT-PCR primer and 
probe set recommended by the United States Centers 
for Disease Prevention and Control (US CDC) for the 
detection of influenza A matrix genes (version 4 
April 2006). RNA copy number was calculated using 
a standard curve of RNA standards (10-fold dilutions) 
of known copy number prepared from a pGEMT-A/
California/7/2009 matrix plasmid using the Riboprobe 
In Vitro Transcription System (Promega, United States). 
Each virus dilution was then tested in each POCT 
according to the manufacturer’s instructions and a 
limit of detection (LOD), based on either the TCID50/
mL or the RNA copy number/µL, was determined. 
Standardising viruses by viral infectivity (TCID50/mL) 
is the most widely used method for the evaluation of 
POCTs, however it does not account for defective viral 
particles which may react in these antigen-detection 
assays. Therefore comparison of the LOD based on both 
TCID50/mL and RNA copy number/µL (which accounts 
for both infective and defective viruses) can be inform-
ative. Half-log10 dilutions of influenza A/Anhui/01/2013 
virus were prepared in duplicate and both sets tested 
with the six POCTs. The number of available test kits 
was not sufficient to conduct duplicate testing of the 
other seven viruses. The duplicate sets of influenza A/
Anhui/01/2013 virus concentrations gave highly com-
parable LOD data, therefore data for only the first set is 
presented. Four of the kits were read by eye, while two 
POCTs (Veritor and Sofia) utilised a mechanical reader 
(Table 1). 
Results 
Based on the TCID50/mL, the LOD of five of the six 
POCTs for the A/Anhui/01/2013 influenza A(H7N9) virus 
ranged from 1x105 to 1x105.5 TCID50/mL, with the Sofia 
and Directigen EZ detecting virus at the lower limit. 
The Clearview POCT was unable to detect the influ-
enza A(H7N9) virus at any of the concentrations tested 
(1x106 TCID50/mL or lower) (Table 2). In comparison, the 
LOD of the POCTs for the other influenza A(H7) viruses 
tested was generally better than that seen with the A/
Anhui/01/2013 virus, with some tests detecting virus 
levels as low as 1x102 TCID50/mL. Seasonal influenza A 
viruses were also more easily detected by most POCTs 
Table 1
Details of influenza point-of-care tests evaluated in this study
Point-of-care test Manufacturer Specimen type approved
Proportion of virus sample 
following addition of diluenta Format 
Time 
(minutes)
Analysis of 
result
SD Bioline Influenza Ag/A/B/
A(H1N1)Pandemic
Standard 
Diagnostics, 
Korea
NPS, NS, NA, 
NPA 50% (S:100 μl + D:100 μl) Test strip 10–15 Eye
Binax Now  
Influenza A & B Card
Alere, Unites 
States
NW, NA, NPS, 
NS 100% (S:100 μl) Card 15 Eye
Clearview Exact  
Influenza A & B
Inverness 
Medical, 
Australia
NS 29% (S: 50 μlb + D:120 μl) Test strip 15 Eye
BD Veritor System for rapid 
detection of Flu A+B
Becton, 
Dickinson, Unites 
States
NS, NPS 11% (S: 50 μlb + D: 400 μl) Cartridge 10 Automated reader
BD Directigen EZ Flu A+B
Becton, 
Dickinson, Unites 
States
NW, NA, NPS, 
TS 83% (S: 300 μl + D: 60 μl) Cartridge 15 Eye
Sofia Influenza A+B FIA Quidel, Unites States
NS, NPS, NPA, 
NW 46% (S: 260 μl + D: 300 ) Cartridge 15
Automated 
reader
D: diluent; NA, nasal aspirate; NPA, nasopharyngeal aspirate; NPS, nasopharyngeal swab; NS, nasal swab; NW, nasal wash; S: specimen.
a Dilution of specimen in kit diluent is presented as a percentage,  where volumes of specimen (S) and diluent (D) are shown in parentheses
b Because the kit is not approved for testing of wash or aspirate samples, the specimen was absorbed by the swab provided after at least a 15 
second immersion in the virus sample. The volume taken up by the swab was found to be approximately 50 μl.
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Table 2
TCID50 limit of detection of the influenza point-of-care tests evaluated in this study
Influenza virus origin/
subtype Designation
Limit of detection (log10 TCID50/mL)
SD Bioline Binax Now Clearview Veritor
Directigen 
EZ Sofia
Human A(H7N9) A/Anhui/01/2013 5.5 5.5 >6a 5.5 5 5
Avian A(H7)
 
 
A/Northern Shoveller Egypt-EMC/1/2012 5 4 >6a 4 4 3
A/Mallard/Netherlands/4/2010 5 4 >6a 4 4 2.5
A/Mallard/Lithuania-EMC/2/2010 4 3 4.5 2.5 2.5 2
Human A(H1N1)pdm09
 
A/Auckland/1/2009 4.5 3.5 5 3 3 2.5
A/Brisbane/292/2010 4 3 4.5 3 2.5 2
Human A(H3N2)
 
A/Sydney/506/2013 5 4 5 4 4 3
A/Victoria/361/2011 4 3.5 4.5 3 3 2.5
TCID50: tissue culture infectious dose 50.
a >6, the virus was not detected at any of the concentrations tested.
Table 3
RNA copy number and Ct value limit of detection of the influenza point-of-care tests evaluated in this study
Influenza virus 
origin/subtype Designation
Limit of detection (RNA copies/µL [Ct value]) RNA copies/
µL [Ct value] of 
1x104.5 TCID50/mL 
concentrations
SD Bioline Binax Now Clearview Veritor
Directigen 
EZ Sofia
Human A(H7N9) A/Anhui/01/2013 5.0x10
5 
[22.2]
5.0x105
[22.2]
>1.5x106 a 
[<20.4]
5.0x105 
[22.2]
1.6x105
[24.0]
1.6x105 
[24.0]
3.6x104
[26.2]
Avian A(H7) A/Northern Shoveller/
Egypt-EMC/1/2012
2.3x106 
[19.7]
2.3x105
[23.3]
>2.9x107 a 
[<15.8]
2.3x105 
[23.3]
2.3x105
[23.3]
2.1x104 
[27.2]
4.1x105
[22.5]
A/Mallard/
Netherlands/4/2010
6.3x105 
[21.6]
5.6x104
[25.7]
>1.1x107 a 
[<17.2]
5.6x104 
[25.7]
5.6x104
[25.7]
6.0x102 
[31.8]
1.3x105
[24.2]
A/Mallard/
Lithuania-EMC/2/2010
7.4x105 
[21.7]
6.6x104
[25.5]
1.5x106 
[20.5]
1.5x104 
[27.6]
1.5x104
[27.6]
8.8x103 
[28.6]
1.5x106
[20.5]
Human A(H1N1)
pdm09 A/Auckland/1/2009
1.2x106 
[20.8]
8.9x104
[25.0]
4.5x106 
[18.8]
5.6x104 
[25.3]
5.6x104
[25.3]
4.6x103 
[28.2]
1.2x106 
[20.8]
A/Brisbane/292/2010 2.7x10
6 
[19.5]
3.2x105
[23.0]
4.5x106 
[19.0]
3.2x105 
[23.0]
5.7x104
[25.5]
1.3x104 
[26.5]
4.5x106  
[19.0]
Human A(H3N2) A/Sydney/506/2013 2.6x10
6 
[19.7]
2.2x105
[23.5]
2.6x106 
[19.7]
2.2x105 
[23.5]
2.2x105
[23.5]
6.3x103 
[26.8]
4.9x105  
[22.2]
A/Victoria/361/2011 5.9x10
5 
[21.9]
1.1x105
[24.3]
1.1x106 
[21.0]
5.7x104 
[26.0]
5.7x104
[26.0]
7.9x103 
[27.8]
1.1x106
[21.0]
Ct: cycle threshold; TCID50: tissue culture infectious dose 50.
a The virus was not detected at any of the concentrations tested.
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than the influenza A(H7N9) virus, with the Sofia kit per-
forming best: LOD ranging from 1x102 to 1x103 TCID50/
mL for the human influenza A(H3N2) and A(H1N1)
pdm09 viruses. 
Comparison of POCT LODs based on RNA copy number/
µL showed similar results to those based on TCID50/mL 
for four of the kits (Binax Now, Clearview, Veritor and 
Sofia). These POCTs were less sensitive for the  detec-
tion of  the influenza A(H7N9) virus compared to the 
seasonal or other influenza A(H7) viruses (Table 3). 
However, for the SD Bioline and the Directigen EZ tests, 
comparison of the LODs based on RNA copy number/µL 
showed that influenza A(H7N9) was detected at a simi-
lar sensitivity to the other viruses (Table 3). 
LODs based on RNA copy number/µL or Ct also allowed 
an estimate of the expected performance of the POCTs 
in detecting influenza A(H7N9) virus in clinical sam-
ples (Figure). Comparison of the published Ct values 
of clinical samples from patients with confirmed influ-
enza A(H7N9) infection [11] suggested that five of the 
six POCTS would have detected only one of the four 
influenza A(H7N9)-positive clinical specimens, with the 
other three specimens being outside the LOD of these 
assays (Figure). 
Discussion
For all viruses tested, the Sofia POCT, which uses an 
automated reader, had the highest sensitivity. The BD 
Veritor test, which also uses an automated reader, had 
comparable sensitivity to the BD Directigen EZ and the 
Binax Now tests, both of which are read by eye. The 
Clearview and SD Bioline POCTs demonstrated the 
poorest sensitivity. 
It is important to note that both the Clearview and the 
BD Veritor tests are only approved for analysis of swab 
specimens, therefore the test method used here may 
not have been appropriate. Similarly, all POCT assays 
may perform better using a particular specimen type, 
which was not tested here. The collection of the virus 
sample used for the Clearview and the BD Veritor 
POCTs (dipping the swab into liquid and waiting at 
least 15 seconds for absorption) resulted in a sample 
volume of approximately 50 μL which, when combined 
with the recommended diluent volume, resulted in the 
lowest concentrations of virus used in this evaluation 
(Table 1). 
Other limitations of this study include the use of only 
a single influenza A(H7N9) isolate A/Anhui/01/2013 
(although this virus is genetically closely related to 
other human influenza A(H7N9) viruses for which 
sequences have been reported) and the fact that clini-
cal specimens were not available for analysis. It is also 
important to note that these POCTs have not been pri-
marily designed or licensed to detect influenza A(H7N9) 
viruses or other avian-derived viruses. 
Nevertheless, this study does demonstrate that the 
sensitivity of at least four of the six evaluated POCTs 
is lower for the novel influenza A(H7N9) virus than for 
seasonal influenza viruses and the other avian influ-
enza A(H7) viruses tested. Comparison with published 
Ct values for clinical specimens from influenza A(H7N9) 
patients suggested that these POCTs may not detect 
the majority of influenza A(H7N9) cases, particularly 
if samples are taken late in the course of disease. 
Therefore RT-PCR remains the diagnostic test of choice 
for the testing of suspected influenza A(H7N9) influ-
enza cases.
Figure
Mean Ct limit of detection for influenza A/Anhui/01/2013 
in point-of-care tests compared with Ct values reported for 
four influenza A(H7N9) cases confirmed by RT-PCR
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Ct: cycle threshold; TCID50: tissue culture infectious dose 50; POCT: 
point-of-care test.
The Ct values of the A/Anhui/01/2013 concentrations containing 
1x106, 1x105.5, 1x105, 1x104.5 TCID50/mL were 20.4, 22.2, 24.0 and 
26.2 respectively, while the RNA copy number was 1.5x106/µL, 
5.0x105/µL, 1.6x105/µL, and 3.6x104/µL  respectively. Error bars 
indicate the standard deviation based on triplicate real-time 
RT-PCR analysis of the virus concentration at the POCT limit of 
detection. Influenza A matrix gene Ct values for the cases were 
27, 32-34, 20 and 27 for the four patients, respectively, and 
were taken from the published article by Chen et al. [11]. RT-PCR 
efficiencies and therefore Ct values may differ slightly between 
the assay used here and that used by Chen et al. Because the 
Clearview POCT did not detect the influenza A/Anhui/01/2013 
virus at any concentration tested, a Ct value of the limit of 
detection could not be determined for this kit.
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